DelveInsight has launched a new report on “Retinoblastoma Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Retinoblastoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Retinoblastoma, historical and forecasted epidemiology as well as the Retinoblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Retinoblastoma Market Report:
- Retinoblastoma is a type of cancer that starts in the retina, the black part of the eye. It is one of the most common types of eye cancer in children
- Although Retinoblastoma is a type of cancer that affects the light-sensitive lining in the retina, the survival rate for Retinoblastoma is 99%
- Retinoblastoma is a rarely affecting cancer that occurs in 1 out of every 16,000-18,000 live births
- Globally Retinoblastoma accounts for 2% of all childhood cancers.
- About 200 to 300 children are diagnosed with Retinoblastoma in the United States each year
Request a sample for the Report: https://www.delveinsight.com/sample-request/retinoblastoma-market
Key benefits of the report:
- Retinoblastoma market report covers a descriptive overview and comprehensive insight of the Retinoblastoma Epidemiology and Retinoblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Retinoblastoma market report provides insights on the current and emerging therapies.
- Retinoblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Retinoblastoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Retinoblastoma market.
Got queries? Click here to know more about the Retinoblastoma Market Landscape
Retinoblastoma Overview:
It is a disease in which malignant (cancer) cells form in the tissues of the retina. Children who have a previous family history of people affected with Retinoblastoma should have an eye exam to check for Retinoblastoma. A genetic mutation (change in the genes of the child) causes Retinoblastoma.
RB1 is the gene that is the cause of Retinoblastoma, the mutation in the cells in the eye grows, uncontrollably, forming a tumor. The chances of a child getting affected by the RB1 mutation is 40% and is often inherited.
Retinoblastoma Symptoms:
The symptoms of Retinoblastoma include-
- A white color pigment in the center (pupil) of the eye
- Eyes appear to be looking in a different direction
- Redness in the eye
- Poor vision
- Swelling in the eye
Retinoblastoma Market
The dynamics of the Retinoblastoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Conbercept ophthalmic injection, Episcleral Topotecan, and others during the forecasted period 2019-2032.
Retinoblastoma Pipeline Therapies:
- Conbercept ophthalmic injection
- Episcleral Topotecan
- Abemaciclib
- Racotumomab
Retinoblastoma Pipeline Key Companies:
- Chengdu Kanghong Biotech
- Targeted Therapy Technologies
- Laboratorio Elea
- Dana-Farber Cancer Institute
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Retinoblastoma Patient Share (%) Overview at a Glance
5. Retinoblastoma Market Overview at a Glance
6. Retinoblastoma Disease Background and Overview
7. Retinoblastoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Retinoblastoma
9. Retinoblastoma Current Treatment and Medical Practices
10. Unmet Needs
11. Retinoblastoma Emerging Therapies
12. Retinoblastoma Market Outlook
13. Country-Wise Retinoblastoma Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Retinoblastoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Retinoblastoma Epidemiology
DelveInsight’s ‘Retinoblastoma Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical, and forecasted Retinoblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com